Skip to main content

Advertisement

Table 1 Characteristics of PAH registries/studies included in the review

From: Pulmonary arterial hypertension in Latin America: epidemiological data from local studies

Characteristic Argentina [29] Brazil [7] Chile [28] HINPULSAR [21] RECOPILAR [22] Chile [27]
Study design and time period Prospective January 2004–March 2012 Prospective January 2008–December 2013 1999–2005 Prospective January 2010–December 2011 Prospective July 2014 – May 2015 Prospective June 2003–March 2005
Number of centres 1 1 2 31 Multicentera 1
Study cohort Group 1 PH Group 1 PH Group 1 PH Group 1 PH Group 1 PH Group 1 PH and Group 4 PH
Percentage of patients with group 1 PH (number of PAH patients) 100% (125) 100% (178) 100% (17) 100% (124) 100% (170) 93% (27)
% IPAH patients 49 29 80 52 52 41
% CTD-PAH 14 26 13 15 15 26
% CHD-PAH 28 8 _ 27 27 33
% Sch-PAH _ 20 _ _ _ _
% Othersb 9 18 7 6 6 _
% female 79 77 60 78 79 86
Mean age (years-old) 34 ± 16 46 ± 15 45 45 ± 17 51 41 ± 14
% FC III/IV 58 46 47 62 70 85
6MWD (m) 360 383 ± 152 348 ± 98 _ 373 378 ± 113
RAP (mm Hg) 8 10 ± 5 12 ± 8 _ 10 8 ± 7
mPAP (mm Hg) 54 52 ± 18 57 ± 15 55 ± 20 _ 59 ± 12
PVR (woods units) 12 10 ± 6 _ _ _ _
CI (L/min/m2) 2 3 ± 1 2 ± 1 _ 3 3 ± 1
Time from onset of symptoms until diagnosis (years) 1.4 _ _ _ _ 2.9
  1. CTD connective tissue disease, CHD congenital heart disease, Sch schistosomiasis-associated, FC functional class, 6MWD 6-minute walking distance, RAP right atrial pressure, mPAP mean pulmonary artery pressure, PVR pulmonary vascular resistance, Cl cardiac index
  2. aThe number of centres was not provided
  3. bOthers: PAH associated to drugs and toxins, associated to HIV and portal hypertension